Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 31;16:3239–3250. doi: 10.2147/NDT.S265478

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

TNA treatment inhibited M1 microglia and promoted M2 microglia in vitro. (A) TNA treatment decreased M1 macrophage (iNOS, TNFα and IL-1β) increased M2 macrophage (CD206, arginase 1 and Ym1) mRNA levels than those in LPS group. No significant changes were found between TNA+ICI group and LPS group. (B) Western blots for iNOS, CD206 and β-actin. TNA treatment decreased iNOS protein about 2.1 folds and upregulated CD206 protein about 2.2 folds than those in LPS group (**P<0.01).

Abbreviations: TNA, tanshinone IIA; IC, ICI 182,780; iNOS, inducible nitric oxide synthase; TNFα, tumor necrosis factor α.